SCHEMBL6793707

SCHEMBL6793707

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1ccccc1-c1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 3/20 0.50
HPGD P15428 1/20 0.50
TP53 P04637 1/20 0.49
CHRNB2 P17787 2/20 0.49
CHRNB4 P30926 2/20 0.49
CHRNA3 P32297 2/20 0.49
CHRNA4 P43681 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
POLB P06746 1/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 2/20 0.48
SMO Q99835 2/20 0.48
GAA P10253 1/20 0.47
ALDH1A1 P00352 1/20 0.47
NR3C1 P04150 1/20 0.47
PPARG P37231 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497806 0.93 CNR1 (0.57) CNR1SMN1; SMN2KDM4EHPGDTP53
SCHEMBL6488474 0.93 CNR1 (0.57) CNR1SMN1; SMN2KDM4EHPGDTP53
SCHEMBL6791511 0.91 HTT (0.57) CNR1KDM4ETP53CHRNB2CHRNB4
SCHEMBL6796673 0.91 HTT (0.59) CNR1KDM4ETP53CHRNB2CHRNB4
SCHEMBL6789227 0.90 LMNA (0.50) CNR1KDM4ETP53CHRNB2CHRNB4
SCHEMBL6792583 0.90 KMT2A (0.56) CNR1KDM4ETP53CHRNB2CHRNB4
SCHEMBL6794391 0.89 HTT (0.49) CNR1SMN1; SMN2KDM4ETP53CHRNB2
SCHEMBL6787263 0.89 HTT (0.49) SMN1; SMN2KDM4ECHRNB2CHRNB4CHRNA3
SCHEMBL6794915 0.89 LMNA (0.49) CNR1KDM4ECHRNB2CHRNB4CHRNA3
SCHEMBL6788981 0.89 HTT (0.49) CNR1KDM4ETP53CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CNR1 695/4885SMN1; SMN2 2504/4885KDM4E 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.